Azoulay Salomon 4
4 · MBX Biosciences, Inc. · Filed May 8, 2026
Research Summary
AI-generated summary of this filing
MBX Biosciences CMO Salomon Sells 231 Shares
What Happened
Azoulay Salomon, Chief Medical Officer of MBX Biosciences (MBX), sold 231 shares of company stock on May 6, 2026, for gross proceeds of approximately $6,824. The sale was reported as an open market/private sale (transaction code S) and reflects a routine sell-to-cover to satisfy tax obligations related to the vesting of restricted stock units.
Key Details
- Transaction date: May 6, 2026. Form 4 filed: May 8, 2026 (timely within the two-business-day window).
- Shares sold: 231 shares; reported weighted-average price: $29.54; aggregate proceeds ≈ $6,824.
- Price range for the aggregate sales: $29.23 to $29.88 (weighted average reported; detailed per-price breakdown available on request per footnote).
- Reason reported (footnote): Mandatory sell-to-cover to cover taxes upon RSU vesting (tax withholding).
- Shares owned after transaction: not specified in the provided filing.
- Transaction codes/notes: S = sale; F (tax withholding) applicable as described in footnote.
Context
Sell-to-cover transactions are routine tax-related disposals that do not necessarily indicate an executive's view on the company's prospects. The filing discloses this was done to satisfy tax obligations connected to RSU vesting and provides a weighted-average sale price and range for the aggregate participant sales.
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-05-06$29.54/sh−231$6,824→ 14,769 total
Footnotes (2)
- [F1]The sales reported on this Form 4 represent shares of common stock sold by the Reporting Person to cover tax obligations in connection with the vesting of restricted stock units, pursuant to a mandatory sell-to-cover agreement between the Reporting Person and the Company.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold on an aggregate basis for all Company participants, at prices ranging from $29.23 to $29.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the aggregate number of shares sold at each separate price within the range set forth in this footnote.